Sector News

Generics squeeze forces Novartis Colorado plant to close, imperiling 450 jobs

October 17, 2017
Life sciences

Some drugmakers are responding to industrywide generics pricing pressure by bulking up via M&A, but not Novartis.

The Swiss company’s Sandoz unit plans to scale back or nix production of some generic drugs, and as a result, it’ll close a 450-employee plant in Broomfield, Colorado, a Novartis spokesman said. The plant will shutter over the next two years, and Novartis will consolidate the production of drug ingredients at a plant in Wilson, North Carolina.

“Novartis is currently experiencing above-average pricing pressure in our U.S. portfolio. With several products no longer competitive in saturated markets, we have made the decision to discontinue or divest these limited growth products to optimize our product portfolio,” the spokesman said via email.

As buyers have consolidated in recent years, they’ve put a price squeeze on copycat drugmakers, spurring double-digit price declines across the industry. And Sandoz isn’t the only company whose manufacturing has taken a hit as a result. In August, Teva—the world’s generics leader—said it would close a whopping 15 plants over the next two years to cut costs.

But that’s not to say Novartis is making cuts across the board. On the contrary, it’s funneled investment and jobs into its manufacturing ops in biologics, an area it’s tabbed for growth.

Back in May, the company said it would add 40 or so jobs to a production site in Morris Plains, New Jersey. That facility focuses on the processes needed to produce Novartis’ CAR-T immuno-oncology treatment, the $475,000 Kymriah, which won FDA approval in late August. And the week before the Morris Plains announcement, the drugmaker said it would add about 350 jobs in Switzerland, mostly in “innovative biologics manufacturing” and development.

Meanwhile, other drugmakers have dealt with the hit to traditional, small-molecule generics by bolstering their portfolios—an option Novartis reportedly looked at last November as it weighed a rumored $8 billion deal for Amneal. That drugmaker instead went to California’s Impax Labs in a pickup unveiled on Tuesday.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach